Cite
HARVARD Citation
Bisogno, G. et al. (2018). Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet oncology. 19 (8), pp. 1061-1071. [Online].